Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease

Huntington's disease (HD) is a progressive neurodegenerative disorder for which there is no effective disease modifying treatment. Following-on from studies in HD animal models, histone deacetylase (HDAC) inhibition has emerged as an attractive therapeutic option. In parallel, several reports have demonstrated a role for histone deacetylase 6 (HDAC6) in the modulation of the toxicity caused by the accumulation of misfolded proteins, including that of expanded polyglutamine in an N-terminal huntingtin fragment. An important role for HDAC6 in kinesin-1 dependent transport of brain-derived neurotrophic factor (BDNF) from the cortex to the striatum has also been demonstrated. To elucidate the role that HDAC6 plays in HD progression, we evaluated the effects of the genetic depletion of HDAC6 in the R6/2 mouse model of HD. Loss of HDAC6 resulted in a marked increase in tubulin acetylation throughout the brain. Despite this, there was no effect on the onset and progression of a wide range of behavioural, physiological, molecular and pathological HD-related phenotypes. We observed no change in the aggregate load or in the levels of soluble mutant exon 1 transprotein. HDAC6 genetic depletion did not affect the efficiency of BDNF transport from the cortex to the striatum. Therefore, we conclude that HDAC6 inhibition does not modify disease progression in R6/2 mice and HDAC6 should not be prioritized as a therapeutic target for HD.

[1]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[2]  G. Mengod,et al.  Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease , 2004, The Journal of Neuroscience.

[3]  C. Deng,et al.  Recent progress in the biology and physiology of sirtuins , 2009, Nature.

[4]  J. Taylor,et al.  HDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy , 2010, The EMBO journal.

[5]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[6]  David Housman,et al.  Huntington's Disease: Can Mice Lead the Way to Treatment? , 2011, Neuron.

[7]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[8]  J. Conner,et al.  Anterograde transport of brain-derived neurotrophic factor and its role in the brain , 1997, Nature.

[9]  R. Kopito,et al.  Aggresomes, inclusion bodies and protein aggregation. , 2000, Trends in cell biology.

[10]  E. Cattaneo,et al.  Brain-derived neurotrophic factor in neurodegenerative diseases , 2009, Nature Reviews Neurology.

[11]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[12]  S. Finkbeiner,et al.  Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* , 2010, The Journal of Biological Chemistry.

[13]  Charles Kooperberg,et al.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. , 2002, Human molecular genetics.

[14]  G. Bates,et al.  Histone deacetylase inhibitors as therapeutics for polyglutamine disorders , 2006, Nature Reviews Neuroscience.

[15]  Susumu Tonegawa,et al.  Brain‐derived neurotrophic factor over‐expression in the forebrain ameliorates Huntington’s disease phenotypes in mice , 2008, Journal of neurochemistry.

[16]  J. Garin,et al.  Identification of Components of the Murine Histone Deacetylase 6 Complex: Link between Acetylation and Ubiquitination Signaling Pathways , 2001, Molecular and Cellular Biology.

[17]  Leslie M Thompson,et al.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Bhide,et al.  Analysis of huntingtin‐associated protein 1 in mouse brain and immortalized striatal neurons , 1999, The Journal of comparative neurology.

[19]  F. Alt,et al.  Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally , 2008, Molecular and Cellular Biology.

[20]  J. Vance,et al.  The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress , 2003, Cell.

[21]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[22]  P. Patterson,et al.  New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins , 2001, Brain Research Bulletin.

[23]  S. Finkbeiner,et al.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease , 2009, Human molecular genetics.

[24]  Michelle K. Lupton,et al.  The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes , 2007, Brain Research Bulletin.

[25]  P. Matthias,et al.  HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo , 2003, The EMBO journal.

[26]  P. Paganetti,et al.  Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction , 2009, Molecular Neurodegeneration.

[27]  P. Matthias,et al.  The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. , 2007, Genes & development.

[28]  E. Wanker,et al.  Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease , 2006, Neurobiology of Disease.

[29]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[30]  P. Dolan,et al.  Histone deacetylase 6 interacts with the microtubule‐associated protein tau , 2008, Journal of neurochemistry.

[31]  Mauro Delorenzi,et al.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.

[32]  Cathryn M Lewis,et al.  Standardization and statistical approaches to therapeutic trials in the R6/2 mouse , 2003, Brain Research Bulletin.

[33]  A. Hart,et al.  Differential Contributions of Caenorhabditis elegans Histone Deacetylases to Huntingtin Polyglutamine Toxicity , 2006, The Journal of Neuroscience.

[34]  C. Cepeda,et al.  Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington’s Disease: Exercise, Adenosine Receptors and Ampakines , 2010, PLoS currents.

[35]  Fabrice P Cordelières,et al.  Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin Acetylation , 2007, The Journal of Neuroscience.

[36]  A. Benraiss,et al.  Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. , 2007, The Journal of clinical investigation.

[37]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[38]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[39]  R. Jiao,et al.  Drosophila Histone Deacetylase 6 Protects Dopaminergic Neurons against α-Synuclein Toxicity by Promoting Inclusion Formation , 2010, Molecular biology of the cell.

[40]  W. Hiddemann,et al.  Assignment1 of the human histone deacetylase 6 gene (HDAC6) to X chromosome p11.23 by in situ hybridization , 2001, Cytogenetic and Genome Research.

[41]  Leslie Michels Thompson,et al.  Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. , 2008, Human molecular genetics.

[42]  Dan Garza,et al.  HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS , 2007, Nature.

[43]  G. Bates,et al.  Genetic Knock-Down of HDAC7 Does Not Ameliorate Disease Pathogenesis in the R6/2 Mouse Model of Huntington's Disease , 2009, PloS one.

[44]  J. Marsh,et al.  CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice , 2008, Molecular and Cellular Neuroscience.

[45]  G. Bates,et al.  Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease , 2009, PloS one.

[46]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[47]  J. Taylor,et al.  HDAC6 at the Intersection of Autophagy, the Ubiquitin-proteasome System, and Neurodegeneration , 2007, Autophagy.

[48]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[49]  Laura A. Mamounas,et al.  Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression , 2004, Journal of Neuroscience Methods.

[50]  Joo-Yong Lee,et al.  Histone Deacetylase 6 Regulates Growth Factor-Induced Actin Remodeling and Endocytosis , 2007, Molecular and Cellular Biology.

[51]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[52]  Dawen Cai,et al.  Microtubule Acetylation Promotes Kinesin-1 Binding and Transport , 2006, Current Biology.

[53]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[54]  H. D. Rosas,et al.  Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. , 2009, Analytical biochemistry.

[55]  G. Bates,et al.  Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease , 2008, Molecular Neurodegeneration.

[56]  R. Kopito,et al.  HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin* , 2005, Journal of Biological Chemistry.

[57]  Chris Frost,et al.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.

[58]  S. Schreiber,et al.  Three proteins define a class of human histone deacetylases related to yeast Hda1p. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[60]  O. Isacson,et al.  Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. , 2008, Human molecular genetics.

[61]  Sharon Y. R. Dent,et al.  HDAC6 modulates cell motility by altering the acetylation level of cortactin. , 2007, Molecular cell.

[62]  E. Wanker,et al.  Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. , 2001, Human molecular genetics.